MarketCap
Facebook
X
Telegram
Viatris EV/EBITDA Ratio | VTRS
Annual EV/EBITDA Ratio Viatris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157 | 7.62 | 12.7 | 8.9 | 10.5 | 23.2 | 8.33 | 9.87 | 11.7 | 11.4 | 12.9 | 14.3 | 15.4 | 10.3 | 8.92 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 157 | 7.62 | 21.5 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
28.9 | - | - | $ 142 M |  USA |
 |
cbdMD
YCBD
|
-2.5 | $ 0.39 | 1.86 % | $ 1.57 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-1.21 | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
-6.14 | $ 0.55 | -2.64 % | $ 2.36 M |  China |
 |
Lannett Company
LCI
|
-4.72 | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
0.644 | - | - | $ 55.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
5.6 | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
4.86 K | - | 1.64 % | $ 400 M | USA |
 |
Tricida
TCDA
|
-3.64 | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
0.585 | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
-3.19 | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
-1.84 | - | -27.8 % | $ 2.56 M | USA |
 |
Catalent
CTLT
|
-64.3 | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
-2.32 | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
-5.28 | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
-13.5 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
47.3 | - | -4.76 % | $ 65.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
-2.44 | $ 0.59 | -5.37 % | $ 176 M |  Canada |
 |
Aurora Cannabis
ACB
|
66.7 | $ 5.11 | -1.07 % | $ 280 M | Canada |
 |
Harrow Health
HROW
|
69.4 | $ 30.4 | 10.67 % | $ 1.12 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
45.3 | $ 5.39 | 0.37 % | $ 80.1 M | USA |
 |
Relmada Therapeutics
RLMD
|
-4.24 | $ 4.24 | 2.42 % | $ 167 M | USA |
 |
Emergent BioSolutions
EBS
|
5.32 | $ 6.04 | -0.98 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
0.428 | $ 3.43 | -3.25 % | $ 1.32 B | Canada |
 |
Evolus
EOLS
|
-18.5 | $ 6.81 | -2.51 % | $ 439 M | USA |
 |
Organogenesis Holdings
ORGO
|
6.81 | $ 0.96 | 5.83 % | $ 122 M | USA |
 |
Bausch Health Companies
BHC
|
8.84 | $ 8.33 | -0.83 % | $ 3.09 B | Canada |
 |
OrganiGram Holdings
OGI
|
-4.08 | $ 0.85 | -2.69 % | $ 81 M | Canada |
 |
Rockwell Medical
RMTI
|
-17.3 | $ 7.35 | -2.26 % | $ 264 M | USA |
 |
SCYNEXIS
SCYX
|
-1.64 | $ 3.54 | 1.14 % | $ 177 M | USA |
 |
HEXO Corp.
HEXO
|
-0.524 | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
2.61 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Sonoma Pharmaceuticals
SNOA
|
-4.44 | $ 1.12 | -0.88 % | $ 1.89 M | USA |
 |
TherapeuticsMD
TXMD
|
-6.57 | $ 1.74 | 2.96 % | $ 20.1 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.504 | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
28.1 | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
5.65 | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
0.799 | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
-4.26 | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.0319 | - | -0.21 % | $ 98 M | USA |
 |
Agile Therapeutics
AGRX
|
-1.28 | - | 10.11 % | $ 58.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-19 | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
14.4 | $ 36.48 | 0.04 % | $ 1.63 B | USA |
 |
Perrigo Company plc
PRGO
|
-8.96 | $ 16.83 | -0.71 % | $ 2.33 B | USA |
 |
Evoke Pharma
EVOK
|
0.599 | - | - | $ 36.6 M | USA |
 |
Solid Biosciences
SLDB
|
-3.47 | $ 7.19 | 2.35 % | $ 629 M | USA |
 |
Sundial Growers
SNDL
|
-52.1 | $ 1.4 | -0.36 % | $ 361 M | Canada |
 |
Tilray
TLRY
|
-17.8 | $ 2.66 | -6.84 % | $ 297 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | USA |